SCHEMBL17716538

SCHEMBL17716538

Cc1nnc(-c2cccc(-c3c(C)c4cc5c6c(c4oc3=O)CCCN6CCC5)c2)c2c1CCC(O)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.39
▸ MEN1 O00255 7/20 0.38
▸ KMT2A Q03164 7/20 0.38
▸ ALDH1A1 P00352 7/20 0.38
▸ USP2 O75604 6/20 0.38
▸ MAPT P10636 6/20 0.38
▸ LMNA P02545 6/20 0.38
▸ KDM4E B2RXH2 5/20 0.38
▸ GAA P10253 5/20 0.38
▸ HPGD P15428 4/20 0.38
▸ CASP1 P29466 4/20 0.38
▸ CASP7 P55210 4/20 0.38
▸ HSD17B10 Q99714 4/20 0.38
▸ TDP1 Q9NUW8 3/20 0.38
▸ GLA P06280 2/20 0.38
▸ ATM Q13315 2/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ KEAP1 Q14145 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17716537 0.89 MCL1 (0.38) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17717163 0.80 ATM (0.41) ATM
SCHEMBL17716539 0.79 ERAP1 (0.38) KMT2AALDH1A1MAPTLMNAKDM4E
SCHEMBL17716529 0.78 MCL1 (0.46) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17716528 0.78 MEN1 (0.45) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17716545 0.74 USP2 (0.46) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17716547 0.72 MEN1 (0.47) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17914323 0.70 ALDH1A1 (0.62) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL14088018 0.70 MEN1 (0.45) MCL1MEN1KMT2AALDH1A1USP2
SCHEMBL17716542 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200188535-A1 Bioorthogonal Turn-on Probes THE GENERAL HOSPITAL CORPORATION 2020-06-18 — — US disclosed
US-20160121002-A1 Bioorthogonal Turn-on Probes THE GENERAL HOSPITAL CORPORATION (US) 2016-05-05 — — US disclosed
US-20160121002-A1 Bioorthogonal Turn-on Probes THE GENERAL HOSPITAL CORPORATION (US) 2016-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160121002-A1 Bioorthogonal Turn-on Probes MPI, TIPRL, BAZ1A MCL1 2007/4885MEN1 381/4885KMT2A 3016/4885
US-20200188535-A1 Bioorthogonal Turn-on Probes ZYX, MPI, BAZ1A MCL1 1846/4885MEN1 477/4885KMT2A 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback